| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
This compound targets the NF-κB signaling pathway. It inhibits the NF-κB p65 subunit in HeLa cells. By inhibiting NF-κB, it can modulate the expression of genes involved in inflammation, cell survival, and proliferation. This makes it a potential agent for studying inflammatory diseases and cancer.
|
|---|---|
| ln Vitro |
In vitro, kaempferol 5,7,4'-trimethyl ether inhibits the growth of HT-29 and CCD-112CoN cells. It also inhibits LPS-induced NO production in RAW 264.7 cells. These activities indicate its potential for colon cancer research and anti-inflammatory studies.
|
| ln Vivo |
In vivo, the activity of kaempferol 5,7,4'-trimethyl ether is primarily inferred from its in vitro properties. As a flavonoid with anti-inflammatory and anticancer activities, it may have similar effects in animal models, but specific in vivo studies are not detailed in the provided search results.
|
| Enzyme Assay |
The in vitro NF-κB inhibition assay for kaempferol 5,7,4'-trimethyl ether can be performed using a reporter gene assay. Cells are transfected with an NF-κB-responsive luciferase reporter plasmid and then treated with the compound. The inhibition of NF-κB activity is measured by the reduction in luciferase activity.
|
| Cell Assay |
In vitro cellular studies are conducted using various cell lines. HeLa cells are used to study the inhibition of the NF-κB p65 subunit. HT-29 and CCD-112CoN cells are used to study its anti-proliferative effects. RAW 264.7 macrophages are used to study the inhibition of LPS-induced NO production. Cells are treated, and the relevant endpoints are measured.
|
| Animal Protocol |
In vivo animal experiments are not detailed in the search results. However, given its in vitro activity, it could be studied in animal models of colon cancer or inflammation. Animals would be administered the compound, and tumor growth or inflammatory markers would be assessed.
|
| ADME/Pharmacokinetics |
Kaempferol 5,7,4'-trimethyl ether has a molecular formula of C18H16O6 and a molecular weight of 328.3 g/mol. It is a flavonoid compound. It appears as a yellow powder. It is soluble in organic solvents like DMSO and ethanol. For research, it is typically stored at -20°C, protected from light and moisture. Its purity is >98%.
|
| Toxicity/Toxicokinetics |
As a flavonoid, it is generally considered to have low toxicity. However, as a research chemical, it is not intended for human use. Standard laboratory safety precautions should be followed. Its safety profile would need to be established through comprehensive toxicology studies.
|
| References | |
| Additional Infomation |
3-Hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromene-4-one has been reportedly found in Aglaia perviridis and Meistera koenigii, and relevant data are available.
Kaempferol 5,7,4'-trimethyl ether is a polymethoxyflavone with potential for colon cancer research. Its ability to inhibit NF-κB and reduce NO production makes it a valuable tool for studying inflammation and cancer pathways. It is a naturally occurring compound found in various plants and is available as a research-grade standard. |
| Molecular Formula |
C18H16O6
|
|---|---|
| Molecular Weight |
328.32462
|
| Exact Mass |
328.094
|
| CAS # |
1098-92-6
|
| PubChem CID |
624831
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
529.6±50.0 °C at 760 mmHg
|
| Melting Point |
150-153℃
|
| Flash Point |
194.3±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
3.38
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
494
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3OC)OC)O
|
| InChi Key |
SGPXJCVFCJANKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O6/c1-21-11-6-4-10(5-7-11)18-17(20)16(19)15-13(23-3)8-12(22-2)9-14(15)24-18/h4-9,20H,1-3H3
|
| Chemical Name |
3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0458 mL | 15.2290 mL | 30.4581 mL | |
| 5 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL | |
| 10 mM | 0.3046 mL | 1.5229 mL | 3.0458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
